Sovateltide Explained

Width:	300px
Tradename:	Tyvalzi
Legal Status:	Rx in India
Synonyms:	IRL-1620; PMZ-1620
Cas Number:	142569-99-1
Pubchem:	16133819
Chemspiderid:	17287647
Chembl:	3188091
Iuphar Ligand:	3886
Iupac Name:	Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH
C:	86
H:	117
N:	17
O:	27
Stdinchi:	1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
Stdinchikey:	DXPHNGAMYPPTBJ-TZMIJSMNSA-N
Smiles:	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O

Sovateltide (development names IRL-1620 and PMZ-1620,^[1] sold in India under the brand name Tyvalzi)^[2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz.^[2] Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis).^[3] ^[4] Sovateltide also protects neural mitochondria and enhances their biogenesis.^[5]

Notes and References

Gulati . Anil . Agrawal . Nilesh . Vibha . Deepti . Misra . U. K. . Paul . Birinder . Jain . Dinesh . Pandian . Jeyaraj . Borgohain . Rupam . Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke . CNS Drugs . January 2021 . 35 . 1 . 85–104 . 10.1007/s40263-020-00783-9 . 33428177 . 7872992 . 1179-1934. free .
Keam . Susan J. . Sovateltide: First Approval . Drugs . September 2023 . 83 . 13 . 1239–1244 . 10.1007/s40265-023-01922-4 . 37486545 . 260114948 . 1179-1950.
Ranjan . Amaresh K. . Gulati . Anil . 2022-03-15 . Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders . International Journal of Molecular Sciences . en . 23 . 6 . 3146 . 10.3390/ijms23063146 . free . 1422-0067 . 8955091 . 35328566.
Ranjan . Amaresh K. . Briyal . Seema . Khandekar . Divya . Gulati . Anil . September 2020 . Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke . Canadian Journal of Physiology and Pharmacology . en . 98 . 9 . 659–666 . 10.1139/cjpp-2020-0164 . 32574518 . 0008-4212.
Ranjan . Amaresh K. . Briyal . Seema . Gulati . Anil . 2020-07-29 . Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke . Scientific Reports . en . 10 . 1 . 12737 . 10.1038/s41598-020-69673-w . 2045-2322 . 7391684 . 32728189. 2020NatSR..1012737R .